Caroline Hedsund

Dr. Caroline Hedsund


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2022 in BMJ Open Respiratory Research
Verified
Journal Article
Open access
PDF file
CHCaroline Hedsund
Caroline Hedsund
PNPhilip Mørkeberg Nilsson
Philip Mørkeberg Nilsson
NHNils Hoyer
Nils Hoyer
DRDaniel Bech Rasmussen
Daniel Bech Rasmussen
CHClaire Præst Holm
Claire Præst Holm
JWJon Torgny Wilcke
Jon Torgny Wilcke
Introduction: Updated treatment guidelines for acute hypercapnic respiratory failure (AHRF) in chronic obstructive pulmonary disease (COPD) with non-invasive ventilation (NIV) in 2016 recommended a rapid increase in inspiratory positive airway pressure (IPAP) to 20 cm H2O with possible further increase for patients not responding. Previous guidelines from 2006 suggested a more conservative algorithm and maximum IPAP of 20 cm H2O. Aim: To determine whether updated guidelines recommending higher IPAP during NIV were related with improved outcome in patients with COPD admitted with AHRF, compared with NIV with lower IPAP. Methods: A retrospective cohort study comparing patients with COPD admitted with AHRF requiring NIV in 2012–2013 and 2017–2018. Results: 101 patients were included in the 2012–2013 cohort with low IPAP regime and 80 patients in the 2017–2018 cohort with high IPAP regime. Baseline characteristics, including age, forced expiratory volume in 1 s (FEV1), pH and PaCO2 at initiation of NIV, were comparable. Median IPAP in the 2012–2013 cohort was 12 cm H2O (IQR 10–14) and 20 cm H2O (IQR 18-24) in the 2017–2018 cohort (p<0.001). In-hospital mortality was 40.5% in the 2012–2013 cohort and 13.8% in the 2017–2018 cohort (p<0.001). The 30-days and 1-year mortality were significantly lower in the 2017–2018 cohort. With a Cox model 1 year survival analysis, adjusted for age, sex, FEV1 and pH at NIV initiation, the HR was 0.45 (95% CI 0.27 to 0.74, p=0.002). Conclusion: Short-term and long-term survival rates were substantially higher in the cohort treated with higher IPAP. Our data support the current strategy of rapid increase and higher pressure.

27 March 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
DADaniel Alexander Ackermann
Daniel Alexander Ackermann
Allan LinnebergAllan Linneberg
Allan Linneberg
EREma Rastoder
Ema Rastoder
AVAnna Kubel Vognsen
Anna Kubel Vognsen
ABAnne Ahrendt Bjerregaard
Anne Ahrendt Bjerregaard
Pradeesh SivapalanPradeesh Sivapalan
Pradeesh Sivapalan
Background: Vitamin K is a cofactor necessary for the biological activity of proteins like Matrix Gla Protein (MGP), which reduce calcification and help preserve lung function. This study aims to determine, first, whether low vitamin K status is associated with chronic obstructive pulmonary disease (COPD), and secondary, whether the level of vitamin K is associated with COPD severity, smoking exposure, or mortality. Methods: The plasma concentration of dephosphorylated uncarboxylated (dp-uc) MGP was used as an inverse biomarker for vitamin K in 98 COPD patients from the CODEX-P COPD study and 986 controls from the DanFunD study. Low vitamin K status was defined as the upper quartile of dp-ucMGP (>589 pmol/L). Using a logistic regression model, we examined whether low vs. high/moderate vitamin K status increased the odds ratio (OR) of having COPD. Secondary analyses, in the COPD cohort only, examined the association between low vitamin K status and COPD severity, smoking exposure in packyears and all-cause mortality, using a Welch’s t-test and log-rank test, respectively. Results: Low vitamin K status was associated with increased odds of having COPD, OR 9.7 (95% CI [5.5 to 17.5], p < 0.001). We found no associations between low vitamin K and COPD severity (est. −0.03, p = 0.7; 95% CI [−0.2 to 0.1]), smoking exposure (p = 0.7), or all-cause mortality (p = 0.5). Conclusions: Low vitamin K status was associated with substantially higher odds of having COPD compared to high/moderate vitamin K status. No association was found between low vitamin K status and COPD severity, smoking exposure, or all-cause mortality. Further studies are needed to determine if vitamin K plays a role in the pathophysiology of COPD and whether supplement therapy is indicated.

Verified
Journal Article
Open access
PDF file
EREma Rastoder
Ema Rastoder
PKPeter Kamstrup
Peter Kamstrup
CHCaroline Hedsund
Caroline Hedsund
AJAlexander Jordan
Alexander Jordan
Pradeesh SivapalanPradeesh Sivapalan
Pradeesh Sivapalan
Jens Ulrik Stæhr JensenJens Ulrik Stæhr Jensen
Jens Ulrik Stæhr Jensen
Chronic Obstructive Pulmonary Disease (COPD) exacerbation is known for its substantial impact on morbidity and mortality among affected patients, creating a significant healthcare burden worldwide. Coagulation abnormalities have emerged as potential contributors to exacerbation pathogenesis, raising concerns about increased thrombotic events during exacerbation. The aim of this study was to explore the differences in thrombelastography (TEG) parameters and coagulation markers in COPD patients during admission with exacerbation and at a follow-up after discharge. This was a multi-center cohort study. COPD patients were enrolled within 72 h of hospitalization. The baseline assessments were Kaolin-TEG and blood samples. Statistical analysis involved using descriptive statistics; the main analysis was a paired t-test comparing coagulation parameters between exacerbation and follow-up. One hundred patients participated, 66% of whom were female, with a median age of 78.5 years and comorbidities including atrial fibrillation (18%) and essential arterial hypertension (45%), and sixty-five individuals completed a follow-up after discharge. No significant variations were observed in Kaolin-TEG or conventional coagulation markers between exacerbation and follow-up. The Activated Partial Thromboplastin Clotting Time (APTT) results were near-significant, with p = 0.08. In conclusion, TEG parameters displayed no significant alterations between exacerbation and follow-up.

9 September 2023 in European Respiratory Journal
Verified
Conference Paper
Closed access
CHCaroline Hedsund
Caroline Hedsund
KAKasper Linde Ankjærgaard
Kasper Linde Ankjærgaard
TSTine Peick Sonne
Tine Peick Sonne
PTPhilip Tønnesen
Philip Tønnesen
EHEjvind Frausing Hansen
Ejvind Frausing Hansen
JWJon Torgny Wilcke
Jon Torgny Wilcke
Introduction: It remains unclear whether long-term non-invasive ventilation (LT NIV) for patients with chronic obstructive pulmonary disease (COPD) improves survival and reduces admissions as results from randomized trials are inconsistent. We aim to determine whether LT NIV initiated after an admission with acute hypercapnic respiratory failure (AHRF), can affect survival and admission rate in COPD patients. Methods: A randomized controlled trial, allocating patients to LT NIV or standard of care after an admission with AHRF treated with acute NIV. The LT NIV provided was aimed to normalize PaCO2 using high pressures. Results: The study was conducted in 2013-2020 and discontinued before full sample size due to slow recruitment. 28 patients were randomized to LT NIV and 27 patients to standard of care. 42% of patients had a history of ≥2 admissions with AHRF. Median IPAP was 24 cmH2O (IQR 20-28). The primary outcome, time to readmission with AHRF or death within 12 months, did not reach significance, hazard ratio 0.53 (95%CI 0.25-1.12) p=0.097. In a competing risk analysis, adjusted for history of AHRF, the odds ratio for AHRF was 0.30 (95%CI 0.11-0.87) p=0.024. The LT NIV group had fewer exacerbations (median 1 (0-1) vs 2 (1-4) p=0.021) and readmissions with AHRF (median 0 (0-1) vs 1 (0-1) p=0.016). Conclusion: No effect on the primary outcome was found, however several secondary outcomes like risk of AHRF, number of episodes of AHRF and exacerbations were all in favor of high intensity LT NIV, especially in selected COPD patients with frequent AHRF.